MedTrace Logo

Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis

NCT00630045 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 392

Last updated 2008-03-06

No results posted yet for this study

Summary

This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .

Conditions

Interventions

DRUG

neoadjuvant chemotherapy with oxaliplatin and capecitabine

oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)

PROCEDURE

resection of liver metastasis

surgery with the aim of R0 resection

Sponsors & Collaborators

  • Peking University

    collaborator OTHER

  • Sanofi

    collaborator INDUSTRY

  • Peking University People's Hospital

    lead OTHER

Principal Investigators

  • Shan Wang, MD · Peking University People's Hospital, Department of General Surgery

  • Lin Shen, MD · Peking University, School of Oncology, Department of GI Oncology

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2010-06-30
Completion
2015-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00630045 on ClinicalTrials.gov